IRONWOOD PHARMACEUTICALS INC (IRWD)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Annual

0 200M 400M 600M FY09: 34.3M FY10: 43.9M FY11: 65.9M FY12: 150.2M FY13: 22.9M FY14: 76.4M FY15: 149.6M FY16: 274M FY17: 298.3M FY18: 346.6M FY19: 428.4M FY20: 389.5M FY21: 413.8M FY22: 410.6M FY23: 442.7M FY24: 351.4M FY25: 296.2M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Gross Profit Annual

0 150M 300M 450M FY16: 272.1M FY17: 279.2M FY18: 313.9M FY19: 404.5M FY20: 386.4M FY16 FY17 FY18 FY19 FY20

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income Annual

-1.1B -700M -350M 0 350M 700M 1.1B FY09: -60.8M FY10: -60.8M FY11: -66.1M FY12: -72.8M FY13: -252M FY14: -169.4M FY15: -102.1M FY16: -51.9M FY17: -15.4M FY18: -150.7M FY19: 120.1M FY20: 142.9M FY21: 232.3M FY22: 250.3M FY23: -945.4M FY24: 93.1M FY25: 98.5M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Net Income Annual

-1.1B -700M -350M 0 350M 700M 1.1B FY09: -73.3M FY10: -51.9M FY11: -64.9M FY12: -72.6M FY13: -272.8M FY14: -189.6M FY15: -142.7M FY16: -81.7M FY17: -116.9M FY18: -282.4M FY19: 21.5M FY20: 106.2M FY21: 528.4M FY22: 175.1M FY23: -1B FY24: 880K FY25: 24M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Cost of Revenue Annual

0 15M 30M 45M FY12: 965K FY13: 7.2M FY14: 5.3M FY15: 12K FY16: 1.9M FY17: 19.1M FY18: 32.8M FY19: 23.9M FY20: 3.1M FY12 FY13 FY14 FY15 FY16 FY17 FY18 FY19 FY20

Operating Cash Flow Annual

-300M -200M -100M 0 100M 200M 300M FY09: -3.4M FY10: -67.9M FY11: -75.2M FY12: -69.6M FY13: -273.4M FY14: -155.6M FY15: -106.9M FY16: -25.9M FY17: -100.8M FY18: -70.9M FY19: 10.7M FY20: 168.8M FY21: 261.9M FY22: 273.8M FY23: 183.4M FY24: 103.5M FY25: 127M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Free Cash Flow Annual

-300M -200M -100M 0 100M 200M 300M FY09: -7M FY10: -85.1M FY11: -84.9M FY12: -83.6M FY13: -282.9M FY14: -159.1M FY15: -111M FY16: -30.1M FY17: -103.6M FY18: -71.2M FY19: 3.5M FY20: 167M FY21: 261.6M FY22: 273.6M FY23: 183.2M FY24: 103.4M FY25: 127M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 70M 140M 210M FY09: 7.1M FY10: 89.7M FY11: 99.9M FY18: 152.6M FY19: 156M FY20: 160.7M FY21: 164.4M FY22: 186.3M FY23: 155.4M FY24: 160.1M FY25: 163M FY09 FY10 FY11 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-7.50 -5.00 -2.50 0.00 2.50 5.00 7.50 Q4 '10: -0.63 Q1 '11: -0.57 Q2 '11: -0.58 Q3 '11: -0.71 Q4 '11: -0.66 Q1 '12: -0.81 Q2 '12: -1.00 Q3 '12: -0.37 Q4 '12: -0.71 Q1 '13: -1.24 Q2 '13: -1.43 Q3 '13: -2.36 Q4 '13: -2.38 Q1 '14: -1.89 Q2 '14: -1.76 Q3 '14: -1.55 Q4 '14: -1.39 Q1 '15: -1.25 Q2 '15: -1.15 Q3 '15: -1.18 Q4 '15: -1.00 Q1 '16: -0.85 Q2 '16: -0.66 Q3 '16: -0.56 Q4 '16: -0.56 Q1 '17: -0.83 Q2 '17: -0.98 Q3 '17: -0.97 Q4 '17: -0.80 Q1 '18: -0.73 Q2 '18: -0.75 Q3 '18: -1.67 Q4 '18: -1.85 Q3 '20: 0.69 Q4 '20: 0.66 Q1 '21: 0.89 Q2 '21: 3.12 Q3 '21: 3.25 Q4 '21: 3.23 Q1 '22: 3.19 Q2 '22: 1.01 Q3 '22: 0.95 Q4 '22: 0.97 Q1 '23: 1.01 Q2 '23: -6.04 Q3 '23: -6.23 Q4 '23: -6.51 Q1 '24: -6.79 Q2 '24: 0.04 Q3 '24: -0.03 Q4 '24: -0.01 Q1 '25: -0.21 Q2 '25: -0.06 Q3 '25: 0.15 Q4 '25: 0.13 Q1 '26: 0.60 Q2 '26: 0.77 Q4 '10 Q4 '12 Q4 '14 Q4 '16 Q4 '18 Q2 '22 Q2 '24 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.